These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 35363269)

  • 1. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
    Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
    Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
    Morgans AK; Smith MR; O'Malley AJ; Keating NL
    Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
    Lu H; Lei X; Zhao H; Elting L; Siricilla M; Ursani MA; Giordano SH; Suarez-Almazor M
    J Bone Miner Res; 2021 May; 36(5):861-871. PubMed ID: 33484602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
    BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA; Hastings FW; Petkov VI
    Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.
    Lin JK; Hearn CM; Getzen E; Long Q; Lee DC; Keaveny TM; Jayadevappa R; Robinson KW; Wong YN; Maxwell KN; Narayan V; Haas NB; Takvorian SU; Bikle DD; Chiang JM; Khan AN; Rajapakse CS; Morgans AK; Parikh RB
    Eur Urol Oncol; 2024 Aug; 7(4):794-803. PubMed ID: 37926618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy.
    Hamid MF; Hayden A; Moujaber T; Turner S; Gurney H; Grossmann M; Wong P
    Med J Aust; 2023 Feb; 218(3):126-130. PubMed ID: 36707898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer.
    Hu J; Aprikian AG; Vanhuyse M; Dragomir A
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1374-1381. PubMed ID: 33022649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
    Matsushima H; Taguchi T; Kodama S; Okubo N; Saito K; Jabłońska K; Fukumoto S; Matsumoto T
    J Bone Miner Metab; 2024 Mar; 42(2):223-232. PubMed ID: 38493435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
    Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
    Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study.
    Ye C; Morin SN; Lix LM; McCloskey EV; Johansson H; Harvey NC; Kanis JA; Leslie WD
    J Bone Miner Res; 2023 May; 38(5):659-664. PubMed ID: 36807916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.
    Greenspan SL; Wagner J; Nelson JB; Perera S; Britton C; Resnick NM
    J Bone Miner Res; 2013 Feb; 28(2):325-32. PubMed ID: 22991066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF
    J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.